Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Imara_Inc.
|
| gptkbp:CEO |
gptkb:Sam_Kintz
|
| gptkbp:clinicalTrialPhase |
Phase 1 (ELVN-001)
|
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
oncology
precision oncology |
| gptkbp:foundedYear |
2019
|
| gptkbp:headquartersLocation |
gptkb:Boulder,_Colorado,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enliven Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
2023
|
| gptkbp:numberOfEmployees |
~50 (2024)
|
| gptkbp:pipeline |
gptkb:ELVN-002
ELVN-001 ELVN-003 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ELVN
|
| gptkbp:website |
https://www.enliventherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Imara_Inc.
|
| gptkbp:bfsLayer |
7
|